Available Treatments

Currently, there are five therapies approved by the FDA. These medications can lower the amount of virus in your body and can prevent you from getting very sick or needing to be in the hospital.

Two medications are pills that can be taken by mouth called oral Antiviral drugs.

  1. Paxlovid
  2. Molnupiravir

(Note: These medications must be taken within 5 days of symptoms)

Three medications require an infusion and are Monoclonal Antibodies and Antiviral medications.

  1. Remdesivir
  2. Bebtelovimab

(Note: These medications must be taken within 7 days of symptoms)

Your doctor will provide the best recommendation for you based on your symptoms, health history, and overall risk of getting a severe COVID-19 infection.

 

Timing is Key

The earlier you start treatment, the better it works. If you test positive for a COVID-19 infection, have mild to moderate symptoms, or have recent exposure, contact your doctor immediately to see if you qualify for any of these options.

COVID-19 treatments are safe and effective. You must have a prescription from an authorized health care professional to receive these medications.

 


Test to Treat Program

Test-to-treat locations are designed to be a “one-stop shop” for individuals seeking diagnosis and treatment of COVID-19 within five (5) days of showing symptoms.

How does the test-to-treat program work?

  1. If you have symptoms of COVID-19, locate a test-to-treat site in Delaware on this page of our web site and follow the facility’s directions for scheduling an appointment or for walk-up patients (where permitted).
  2. Once at the site, you will receive a rapid COVID-19 test.
  3. If the test is positive for COVID-19, you will meet with an on-site health care provider to discuss treatment options. There are clinical/medical eligibility criteria for these medications set by the FDA. A positive test alone does not guarantee treatment. You will need to discuss your situation with a provider to determine if you meet the requirements.
  4. If you and the health care provider determine one of the available treatments is best for you, you will receive the medication to take home or a prescription which can be filled at your pharmacy.

Locations

The goal is to have at least one location in each county by the end of May. Additional sites will be added as they are confirmed.

  • Newark Urgent Care, 324 E. Main Street, Newark  – Newark Urgent Care will accept both walk-in patients and patients who make an appointment online (https://newarkurgentcare.org/).  Making an online appointment reduces wait times.  The facility is open 24 hours a day and anyone who comes in will be evaluated and offered the test-to-treat program if they meet the criteria.
  • Atracare, 18068 Coastal Highway, Lewes  – Atracare requests that patients make an appointment online (www.atracare.com) or via text message at 302-517-1385.  The facility is open from 8:00 a.m. to 8:00 p.m. daily and anyone who schedules an appointment will be evaluated and offered the program if they meet the criteria.  Available treatments if deemed appropriate at this facility include monoclonal antibody injections and prescriptions for oral antivirals.
  • Henrietta Johnson Medical Center and all Westside Family Healthcare locations are offering the program to their current patients only at this time. If you are a patient of either facility and would like information about how to participate in the program, please contact the facility directly.

What are monoclonal antibodies?

Monoclonal antibodies (mAB) are laboratory-made proteins that help fight the virus that causes COVID-19. Although mAB treatment is not a cure, it may lessen the severity of symptoms and help keep high-risk patients out of the hospital.

Treatments vary depending on whether they are administered as part of Pre-Exposure Prophylactics (PrEP) or Post-Exposure Prophylactics (PEP). Contact your health care provider to see if you are eligible for either of these treatments.

 


Who is eligible to get monoclonal antibody treatments?

There are severe shortages of COVID-19 treatments. Only those that meet eligibility conditions below are eligible to get monoclonal antibody treatments.

Referral from a health care provider is required for patient treatment.

 

Pre-exposure Treatments

Some immunocompromised individuals who have no known exposure to COVID-19 or with a negative COVID-19 test are eligible for pre-exposure treatment. Eligible adults and pediatric individuals include those who:

  • Are immunocompromised or not expected to mount an immune response to COVID-19 vaccines, or
  • Are not able to be fully vaccinated against COVID-19 due to history of adverse reactions

 

Post-exposure Treatments

Individuals at high risk of severe COVID-19 who have tested positive for COVID-19 and have had 10 days of symptom onset are eligible for post-exposure treatment.

There are currently no approved therapies for post-exposure prophylaxis. Speak with your provider for the latest information.

Patients already hospitalized or those that require oxygen therapy should not take monoclonal therapy.

 


What are oral antiviral treatments?

Oral antiviral therapies are products authorized by the FDA for treatment of COVID-19. These therapies require a prescription by a licensed and authorized provider. Patients should coordinate with their health care provider prior to contacting a location to receive these therapies.

 


Who is eligible to get oral antiviral treatment?

There are severe shortages of COVID-19 treatments. Only those that meet eligibility conditions below are eligible to get monoclonal antibody treatments.

Referral from a health care provider is required for patient treatment.

The treatment is authorized for patients meeting the criteria specified in the FDA’s Emergency Use Authorizations (EUAs) for these treatments. Due to extremely limited supply, patients must:

  • Have tested positive for COVID-19 and have had symptoms for 5 days or less
  • Be at high risk for progression to severe COVID-19, including hospitalization or death
  • Meet certain criteria depending on the antiviral

Please contact your health care provider to see if you are eligible for either of these treatments.

 


People who received SARS-CoV-2 antibody-based products

People who previously received antibody products (anti-SARS-CoV-2 monoclonal antibodies or convalescent plasma) as part of COVID-19 treatment, post-exposure prophylaxis, or pre-exposure prophylaxis can be vaccinated at any time; COVID-19 vaccination does not need to be delayed following receipt of monoclonal antibodies or convalescent plasma. Although some reduction in vaccine-induced antibody titers was observed in people who previously received antibody products, the clinical significance of this reduction is unknown, and the balance of benefits vs. risks favors proceeding with vaccination even considering the possibility of diminished vaccine effectiveness in this situation. Those who received antibody products due to a recent SARS-CoV-2 infection should follow the guidance in the section above.

Special situation: administration of tixagevimab/cilgavimab (EVUSHELD™) for pre-exposure prophylaxis should be deferred for at least two weeks after receipt of a dose of COVID-19 vaccine, per the product EUA. See COVID-19 vaccination and EVUSHELD™ for more information on the timing of EVUSHELD™ administration.

Additional Resources


Get More COVID Data

For more data on Delaware COVID cases, testing and outcomes, including demographic breakdowns, go to My Healthy Community